Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17842830 | 1.00 | CHRNA7 (0.80) | CHRNA7HTR3A | |
| SCHEMBL19739645 | 1.00 | CHRNA7 (0.80) | CHRNA7HTR3A | |
| Hydrochloric Acid SCHEMBL19739770 | 0.99 | CHRNA7 (0.78) | CHRNA7HTR3A | |
| Hydrochloric Acid SCHEMBL19739768 | 0.99 | CHRNA7 (0.78) | CHRNA7HTR3A | |
| SCHEMBL17842753 | 0.92 | CHRNA7 (0.80) | CHRNA7HTR3A | |
| SCHEMBL19739858 | 0.92 | CHRNA7 (0.80) | CHRNA7HTR3A | |
| SCHEMBL19740672 | 0.92 | CHRNA7 (0.80) | CHRNA7HTR3A | |
| Hydrochloric Acid SCHEMBL19739992 | 0.91 | CHRNA7 (0.78) | CHRNA7HTR3A | |
| Hydrochloric Acid SCHEMBL19739995 | 0.91 | CHRNA7 (0.78) | CHRNA7HTR3A | |
| SCHEMBL19740851 | 0.89 | CHRNA7 (1.00) | CHRNA7HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3623371-A1 | GEMINAL SUBSTITUTED QUINUCLIDINE AMIDE COMPOUNDS AS AGONISTS OF ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTORS | Axovant Sciences GmbH (CH) | 2020-03-18 | — | — | EP | disclosed |
| EP-3233087-B1 | GEMINAL SUBSTITUTED QUINUCLIDINE AMIDE COMPOUNDS AS AGONISTS OF ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTORS | AXOVANT SCIENCES GMBH (DE) | 2019-10-02 | — | — | EP | disclosed |
| US-10183938-B2 | Geminal substituted quinuclidine amide compounds as agonists of α-7 nicotonic acetylcholine receptors | AXOVANT SCIENCES GMBH (CH) | 2019-01-22 | — | — | US | disclosed |
| US-20170369486-A1 | GEMINAL SUBSTITUTED QUINUCLIDINE AMIDE COMPOUNDS AS AGONISTS OF ALPHA-7 NICOTONIC ACETYLCHOLINE RECEPTORS | AXOVANT SCIENCES GMBH (CH) | 2017-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10183938-B2 | Geminal substituted quinuclidine amide compounds as agonists of α-7 nicotonic acetylcholine receptors | CHRNA7, CHRNA6, CHRNA5 | CHRNA7 1/4885HTR3A 626/4885 |
| US-20170369486-A1 | GEMINAL SUBSTITUTED QUINUCLIDINE AMIDE COMPOUNDS AS AGONISTS OF ALPHA-7 NICOTONIC ACETYLCHOLINE RECEPTORS | CHRNA7, CHRNA6, CHRNA5 | CHRNA7 1/4885HTR3A 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.